Morquio syndrome

Morquio syndrome
Classification and external resources
Specialty endocrinology
ICD-10 E76.2
ICD-9-CM 277.5
OMIM 253000 253010
DiseasesDB 30807 30806
MedlinePlus 001206
eMedicine ped/1477
Patient UK Morquio syndrome
MeSH D009085

Morquio syndrome (referred to as mucopolysaccharidosis IV, MPS IV, Morquio-Brailsford syndrome, or Morquio)[1] is an autosomal recessive mucopolysaccharide storage disease (see also lysosomal storage disorder), usually inherited.[2]:544 It is a rare type of birth defect with serious consequences. In the US, the incidence rate for Morquio is estimated at between 1 in 200,000 and 1 in 300,000 live births.[1]

When the body cannot process certain types of mucopolysaccharides, they build up or are eliminated, causing various symptoms. These involve accumulation of keratan sulfate.[3]

History

The condition was first described, simultaneously and independently, in 1929, by Luis Morquio (1867–1935),[4] a prominent Uruguayan physician who discovered it in Montevideo, and James Frederick Brailsford (1888–1961), an English radiographer in Birmingham, England.[5][6] They both recognized the occurrence of corneal clouding, aortic valve disease, and urinary excretion of keratan sulfate. Morquio observed the disorder in four siblings in a family of Swedish extraction and reported his observations in French.

Signs

The following signs are associated with Morquio's syndrome:

Symptoms

Patients with Morquio syndrome appear healthy at birth.[1] They often present with spinal deformity, and there is growth retardation and possibly genu valgum in the second or third year of life. A patient with Morquio's syndrome is likely to die at an early age. Symptoms of the disease may include:

Regarding the life span of people with Morquio, some can die as early as 2 or 3 years old, and some can live up to 60 or 70 years old.

Treatment

The treatment for Morquio syndrome consists of prenatal identification and of enzyme replacement therapy. On 12 February 2014, the US Food and Drug Administration approved the drug elosulfase alfa (Vimizim) for treating the disease.[7]

See also

References

  1. 1 2 3 "MPS IV (Morquio syndrome)". MPSSociety.org. National MPS Society. Retrieved 14 January 2015.
  2. ↑ James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
  3. ↑ Prat C, Lemaire O, Bret J, Zabraniecki L, Fournié B (May 2008). "Morquio syndrome: Diagnosis in an adult". Joint Bone Spine 75 (4): 495–8. doi:10.1016/j.jbspin.2007.07.021. PMID 18456538.
  4. ↑ Morquio, L. (1929). "Sur une forme de dystrophie osseuse familiale". Archives de médecine des infants (Paris) 32: 129–135. ISSN 0365-4311.
  5. ↑ synd/2108 at Who Named It?
  6. ↑ Brailsford, J. F. (1929). "Chondro-osteo-dystrophy: Roentgenographic & clinical features of a child with dislocation of vertebrae". American Journal of Surgery (New York) 7 (3): 404–410. doi:10.1016/S0002-9610(29)90496-7.
  7. ↑ "FDA approves Vimizim to treat rare congenital enzyme disorder" (Press release). US Food and Drug Administration. 14 February 2014. Retrieved 14 January 2015.

External links

This article is issued from Wikipedia - version of the Tuesday, May 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.